• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Two Drug Combination Doubled Kidney Cancer Progression Free Survival

0
  • by Peter Goodwin
  • in AJO · Audio · Oncology
  • — 7 Nov, 2018
Two Drug Combination Doubled Kidney Cancer Progression Free Survival
Robert Motzer MD, New York
Two Drug Combination Doubled Kidney Cancer Progression Free Survival
AudioMedica News
Two Drug Combination Doubled Kidney Cancer Progression Free Survival
Two Drug Combination Doubled Kidney Cancer Progression Free Survival
00:00 / 9 minutes
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed

Subscribe: Apple Podcasts | Spotify | Stitcher

MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib plus the anti-programmed death one ligand (PD-L1) avelumab in comparison with those receiving standard sunitinib anti-VEGF therapy in the randomized phase threeJAVELIN Renal 101 clinical trial. Findings were reported at the 2018 annual congress of the European Society for Medical Oncology (ESMO).  http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=LBA6_PR

Robust PFS

“The progression free survival was so robust, the objective response rate was robust [and] the safety profile was favorable that [this] warrants this combination as a new standard of care in patients with advanced kidney cancer,”  lead investigator of the study Robert J Motzer MD PhD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York told the Audio Journal of Oncology.

Share

Tags: alternative to sunitinibavelumabaxitiinibrenal cell cancer

You may also like...

  • Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds 6 Feb, 2014
  • John Gribben Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013
  • ASCO Audio Journal of Oncology in Advance -July 1st, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 ASCO Audio Journal of Oncology in Advance -July 1st, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007 1 Jul, 2007
  • Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer 18 Jul, 2018

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 
  • Next story Which New Combination for Metastatic Renal Cell Cancer?
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Palbociclib Combination Prolongs Life After Breast…
    • BRCA1/2 Ovarian Cancer—Three Years Disease Free…
    • ALK—Targeted Lung Cancer Drugs Benefited Real…
    • Long Overall Survival in Ceritinib-Treated…
  • Home
  • Oncology
  • AJO
  • Two Drug Combination Doubled Kidney Cancer Progression Free Survival

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.